Head to Head Survey: Novelion Therapeutics (NASDAQ:NVLN) & Lipocine (NASDAQ:LPCN)

Lipocine (NASDAQ:LPCN) and Novelion Therapeutics (NASDAQ:NVLN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Analyst Recommendations

This is a summary of recent recommendations for Lipocine and Novelion Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lipocine 0 1 1 0 2.50
Novelion Therapeutics 0 0 0 0 N/A

Lipocine presently has a consensus target price of $3.00, indicating a potential upside of 118.98%. Given Lipocine’s higher possible upside, research analysts clearly believe Lipocine is more favorable than Novelion Therapeutics.

Institutional and Insider Ownership

6.6% of Lipocine shares are held by institutional investors. Comparatively, 35.0% of Novelion Therapeutics shares are held by institutional investors. 6.8% of Lipocine shares are held by insiders. Comparatively, 3.6% of Novelion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Lipocine has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Novelion Therapeutics has a beta of 2.12, indicating that its stock price is 112% more volatile than the S&P 500.


This table compares Lipocine and Novelion Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lipocine N/A -221.27% -90.79%
Novelion Therapeutics -79.43% N/A -26.13%

Earnings & Valuation

This table compares Lipocine and Novelion Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lipocine $170,000.00 529.34 -$13.01 million ($0.50) -2.74
Novelion Therapeutics $130.43 million 0.11 -$108.33 million N/A N/A

Lipocine has higher earnings, but lower revenue than Novelion Therapeutics.


Lipocine beats Novelion Therapeutics on 6 of the 11 factors compared between the two stocks.

About Lipocine

Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that completed Phase II testing; LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth and has completed an end-of-Phase II meeting with the Food and Drug Administration; and LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase I Clinical trial for the treatment of non-alcoholic steatohepatitis. Lipocine Inc. is headquartered in Salt Lake City, Utah.

About Novelion Therapeutics

Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.